# Efficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment)

> **NCT06653569** · PHASE3 · RECRUITING · sponsor: **Dre Pauline Vetter** · enrollment: 484 (estimated)

## Conditions studied

- Influenza Disease; Flu

## Interventions

- **DRUG:** Baloxavir Marboxil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06653569
- **Lead sponsor:** Dre Pauline Vetter
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-13
- **Primary completion:** 2027-04
- **Final completion:** 2027-09
- **Target enrollment:** 484 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- Swiss National Science Foundation
- University Hospital, Geneva
- University of Geneva, Switzerland
- Ente Ospedaliero Cantonale, Ticino, Switzerland
- Centre Hospitalier Universitaire Vaudois (Switzerland)
- University of Zurich
- University Hospital, Zürich

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06653569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06653569, "Efficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06653569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*